Retinalamin
What is Retinalamin?
Retinalamin is a peptide-based medication derived from animal retinal tissue (calves). It represents a breakthrough in treating degenerative eye diseases, particularly those affecting the retina. Retinalamin stimulates photoreceptor regeneration, improves metabolism in the retinal pigment epithelium (RPE), enhances microcirculation in retinal blood vessels, and has been shown to restore visual acuity, expand visual fields, and slow the progression of retinal degeneration. It is used extensively in Russia for glaucoma, macular degeneration, diabetic retinopathy, and post-traumatic retinal dystrophies. The medication must be administered via injection—either parabulbar (near the eye) or intramuscularly.
Mechanism of Action
Stimulates regeneration of photoreceptor cells (rods and cones), improves metabolic activity in retinal pigment epithelium, enhances microcirculation in retinal vessels, and provides trophic support to all retinal cell layers.
Benefits
- Restores and improves visual acuity
- Expands visual fields in glaucoma and retinal dystrophies
- Slows progression of age-related macular degeneration
- Supports recovery from retinal injuries and inflammation
Clinical Applications
Typical Dosage
- 5-10mg once daily parabulbar or intramuscularly for 5-10 days; repeat every 3-6 months as needed
Side Effects
While generally considered safe when used correctly, potential side effects should be monitored. Discontinue use if adverse reactions occur.